Cabaletta Bio (NASDAQ: CABA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Cabaletta’s safety data from the second dose cohort at a dose of 100M DSG3-CAART cells in the DesCAARTes Phase 1 in mucosal pemphigus vulgaris continue to demonstrate no clinically relevant adverse events or DLTs observed during the 28-day monitoring period following infusion. We find today’s announcement especially encouraging, as the data demonstrate the potential for persistent activity and dosing approaching that of oncology but without the need for preconditioning, which we believe makes the approach highly attractive for non-oncology conditions. With dosing underway in Cohort 3, at a dose of 500M DSG3-CAART cells, everything appears on track with this novel approach to treating autoimmune disorders, with initial target engagement/efficacy data expected in the coming months.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About Cabaletta Bio Inc.
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (“CABA(TM)”) platform, in combination with Cabaletta’s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes(TM) phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes(TM) Phase 1 clinical trial, visit www.CabalettaBio.com/patients/descaartes-phase-1-trial. The company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit the company’s website at www.CabalettaBio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
